Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Recruiting now

Conditions studied: Breast Carcinoma

In brief

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Key facts

Study ID

NCT02610426

Run by

National Cancer Institute (NCI)

People needed

162

Starts

2014-03-25

Expected to finish

2100-01-01

Last updated by the study team

2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• European American patients with DNA available
• European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
• African American cases (based on a drop in left ventricular ejection fraction [LVEF] < 50 or a drop from baseline > 20 points) and African American controls

Where it is running

• Eastern Cooperative Oncology Group — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.